Registered Attendees

Registered Attendees

Print This Page

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Close Window
Keystone Resort Floorplan

Keystone Resort Floorplan

Print This Page



Close Window

This meeting took place in 2014



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7)


Organizer(s) Patrick A. Lewis, Thomas Gasser and Marcel P. van der Brug
March 2—7, 2014
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Nov 5, 2013
Abstract Deadline: Dec 5, 2013
Scholarship Deadline: Nov 5, 2013
Discounted Registration Deadline: Jan 8, 2014

Sponsored by Curemark, LLC


Summary of Meeting:
Our understanding of the causes of Parkinson’s disease has undergone a revolution in the last twenty years, driven by advances in cellular neuroscience and molecular genetics. Identification of rare autosomal Mendelian genes causative for Parkinsonism and recent genome wide association studies have revealed novel mechanisms that underlie neuronal death. The themes emerging from these advances, especially protein aggregation, immune response and mitochondrial dysfunction, highlight the overlap with other neurodegenerative diseases such as Alzheimer’s. This meeting will cover our current state of knowledge of the global genetic architecture of Parkinson’s, how this is informing cellular and molecular approaches to the etiology of the disease, and the implications of these discoveries in patient diagnosis and development of novel treatments for Parkinson’s disease. In combination with the parallel meeting on Alzheimer’s disease, it will explore the commonalities between these two devastating disorders and discuss how recent advances in each field can be used to accelerate research.

View Scholarships/Awards

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 2

16:00—20:00
Arrival and Registration


MONDAY, MARCH 3

07:00—08:00
Breakfast

08:00—09:00
Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* John Q. Trojanowski, University of Pennsylvania, USA

Michel Goedert, Medical Research Council, UK
Alzheimer’s Disease and Parkinson’s Disease Are Protein Misfolding Diseases

09:00—11:30
Phenotypic and Genotypic Complexity of AD and PD (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Andrew B. Singleton, NIA, National Institutes of Health, USA
Genetics of AD and PD

Christian C. Raiss, University of Twente, Netherlands
Short Talk: Morphological and Functional Heterogeneity of Lewy Body-Like Inclusions in a Cell Model System

Tina L. Beckett, University of Kentucky, USA
Short Talk: Cerebrovascular Pathology and Neuroinflammatory Changes in a Novel Mouse Model of Mixed Dementia

Dennis W. Dickson, Mayo Clinic, USA
Pathological Overlap of AD and PD

Ryan J. Watts, Genentech, Inc., USA
Overcoming Barriers in Alzheimer’s Drug Development

09:40—10:00
Coffee Break

11:30—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:30—16:30
On Own for Lunch and Recreation

16:00—16:30
Coffee Available

16:30—18:30
Genome-Wide Association and PD
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Andrew B. Singleton, NIA, National Institutes of Health, USA

Thomas Gasser, University of Tübingen, Germany
GWA Studies in PD: New Pathways and Old Targets

Vincent Plagnol, University College London, Genetics Institute, UK
Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus

George T. Kannarkat, Emory University School of Medicine, USA
Short Talk: The rs3129882 Single Nucleotide Polymorphism Alters MHC-II Expression and May Increase Susceptibility for Parkinson’s Disease by Modulating Immune Responses

Haydeh Payami, Wadsworth Center, New York State Department of Health, USA
Interaction between Genes and Environment in PD

16:30—18:30
Genetics of AD
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Virginia M.-Y. Lee, University of Pennsylvania School of Medicine, USA

Christine Van Broeckhoven, VIB, University of Antwerp, Belgium
Genetics of Early-Onset Alzheimer Disease: What Is Missing?

Richard Mayeux, Columbia University, USA
The Search for Functional Genetic Variants in Late-Onset Alzheimer's Disease

Philip L. De Jager, Brigham & Women's Hospital, USA
Short Talk: Deconstructing the Epigenomic Architecture of the Cortex in Alzheimer’s Disease

Gerard D. Schellenberg, University of Pennsylvania, USA
New AD Risk Factor Genes from GWAS

18:30—19:30
Social Hour w/ Lite Bites

19:30—22:00
Poster Session 1


TUESDAY, MARCH 4

07:00—08:00
Breakfast

08:00—11:15
Biomarkers of AD and PD (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Clifford R. Jack, Mayo Clinic, USA

Kenneth L. Marek, Institute for Neurodegenerative Disorders, USA
Parkinson's Progression Marker Initiative: Developing a Translational Toolbox for Parkinson's Disease

Kaj Blennow, University of Gothenburg, Sweden
CSF Biomarkers for AD: Approaching the End of the Long Road to Validated and Approved Biomarkers

Anna Cartier, ICB International, Inc., USA
Short Talk: A Novel Blood-Brain Barrier Permeable PET Ligand for Parkinson’s Disease

Juliya Kalinina, Merck & Co., USA
Short Talk: Highly Sensitive and Selective Amyloid Oligomer Biomarker Assay Differentiates Alzheimer’s from Non-AD Cerebrospinal Fluid (CSF) and Tissues

Thomas J. Montine, University of Washington Medical Center, USA
Modifiable Factors Associated with Free Radical Injury in the Aging Brain

Alice S. Chen-Plotkin, University of Pennsylvania School of Medicine, USA
Unbiased Approaches to Parkinson's Disease Biomarker Discovery

09:20—09:40
Coffee Break

11:15—12:45
Future Opportunities and Obstacles in PD Research

NOTE: Jamie Eberling of the Michael J. Fox Foundation will host a short forum bringing together PD researchers and some of the funding bodies to discuss future opportunities and obstacles in PD research, and how the research and funding community can work together to take advantage/overcome these obstacles.

11:15—13:00
Poster Setup

13:00—22:00
Poster Viewing

12:45—16:30
On Own for Lunch and Recreation

14:30—16:30
Panel: Combo Therapy for AD

* Dennis J. Selkoe, Harvard Medical School, USA

Ryan J. Watts, Genentech, Inc., USA

Charles F. Albright, Bristol-Myers Squibb, USA

Michael K. Ahlijanian, Pfizer Inc., USA
Pros and Cons of Combo Therapy from a Biopharma Drug Discovery and Development Perspective

Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA
Pros and Cons of Combo Therapy from a Clinical Researcher and the Patient's Perspective

16:00—16:30
Coffee Available

16:30—18:30
Mitochondrial Biology and the Pathology of PD
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Mark R. Cookson, NIA, National Institutes of Health, USA

Richard J. Youle, NINDS, National Institutes of Health, USA
Role of PINK1 and Parkin on Mitochondria Quality Control in vitro and in vivo

Helene Marie Plun-Favreau, University College London Institute of Neurology, UK
Missing Pieces in the Mitophagy Puzzle

J. Wade Harper, Harvard Medical School / Biogen Idec
Short Talk: Parkin-Dependent Ubiquitin Chain Synthesis in vivo and in vitro

Alex J. Whitworth, University of Sheffield, UK
Drosophila Models of Parkinson's Disease

16:30—18:30
AD Biomarkers
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Thomas J. Montine, University of Washington Medical Center, USA

Daniel M. Skovronsky, Avid Radiopharmaceuticals, Inc., USA
Amyloid Imaging

David M. Holtzman, Washington University, USA
Sleep and Circadian Rhythms: Potential Bidirectional Relationship with Alzheimer’s Disease

Clifford R. Jack, Mayo Clinic, USA
Alzheimer’s Disease Biomarkers

Wendy Wei Qiao Qiu, Boston University School of Medicine, USA
Short Talk: Amylin and its Analog: Potential Diagnostic Test and Therapeutic Drug for Alzheimer’s Disease

18:30—19:30
Social Hour w/ Lite Bites

19:30—22:00
Poster Session 2


WEDNESDAY, MARCH 5

07:00—08:00
Breakfast

08:00—11:15
What Are the Toxic Species of Tau, Abeta and alpha-Synuclein (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Karen Hsiao Ashe, University of Minnesota, USA
Relevance of Quaternary Structure to the Functional Effects of beta-Amyloid Oligomers in the Brain

Dennis J. Selkoe, Harvard Medical School, USA
Protein Misfolding in AD and PD: New Mechanistic Insights

Danielle Mor, University of Pennsylvania, USA
Short Talk: The Role of Dopamine in Generating Toxic Oligomeric Conformers of Alpha-Synuclein

Vincent Raussens, Université Libre de Bruxelles, Belgium
Short Talk: Unraveling the Interaction between apoE and Amyloid beta Peptide Using Crosslinking and Mass Spectrometry

Vikram Khurana, Whitehead Institute for Biomedical Research and Massachusetts General Hospital, USA
A-Synuclein Toxicity: Phenotypic Screen from Yeast to Patient iPSc Cells

* Hui Zheng, Baylor College of Medicine, USA
Clearance of Toxic Tau Proteins and Rescue of Neurotoxicity by TFEB

09:20—09:40
Coffee Break

11:15—12:45
NIH Panel (Joint): New AD and PD Recommendations

Creighton Tony Phelps, NIA, National Institutes of Health, USA

Thomas J. Montine, University of Washington Medical Center, USA

Beth-Anne Sieber, NINDS, National Institutes of Health, USA

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing

12:45—16:30
On Own for Lunch and Recreation

16:00—16:30
Coffee Available

16:30—18:30
Pluripotent Stem Cells and Inherited PD
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Patrick A. Lewis, University of Reading, UK

Tilo Kunath, University of Edinburgh, UK
Alpha-Synuclein Dysfunction in Pluripotent Stem Cell Derived Neurons

Dimitri Krainc, Northwestern University, USA
Links between Lysosomal Dysfunction and Neurodegeneration

Birgitt Schuele, Parkinson's Institute, USA
Short Talk: Mitochondrial Dysfunction in Patient-Derived LRRK2 Stem Cell Models

Jared Sterneckert, Max-Planck-Institut für Molekulare Biomedizin, Germany
Modeling Parkinson’s Disease Induced by Mutant LRRK2 Using Isogenic Human iPSCs

16:30—18:30
Transmission of Tau and Abeta
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Michael K. Ahlijanian, Pfizer Inc., USA

John Q. Trojanowski, University of Pennsylvania, USA
Transmission of Tau Pathology: A New Model for the Progression of Tauopathies

Virginia M.-Y. Lee, University of Pennsylvania School of Medicine, USA
Transmission of alpha-Synculein in Parkinson’s Disease

Zeshan Ahmed, Eli Lilly and Company, UK
Short Talk: A Novel in vivo Model of Tau Propagation that Is Suitable for Evaluating the Efficacy of Tau-Based Therapeutic Strategies

Karen Duff, Columbia University, USA
Propagation of Pathology and Functional Decline in AD

18:30—19:30
Social Hour w/ Lite Bites

19:30—22:00
Poster Session 3


THURSDAY, MARCH 6

07:00—08:00
Breakfast

08:00—11:15
Passive Immunization and Other Novel Therapies to Treat AD and PD (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Ryan J. Watts, Genentech, Inc., USA

Eliezer Masliah, University of California, San Diego, USA
Passive Immunization Therapies for Parkinson’s Disease

Kurt R. Brunden, University of Pennsylvania, USA
Microtubule Stabilizing Drugs to Treat Axonal Transport Failure in AD and PD

Zdenek Berger, Pfizer, USA
Short Talk: Effects of Tool Compounds on Glucocerebrosidase Activity in Human and Mouse Brain Lysates

Eva Czirr, VA Palo Alto / Stanford University, USA
Short Talk: Complement Receptor 3 Deficiency Reduces Alzheimer’s Disease Amyloid Pathology in Mice

Marc Mercken, Janssen R&D, Belgium
Translating Alzheimer’s Disease Science into Breakthrough Therapies

Michael K. Ahlijanian, Pfizer Inc., USA
Challenges Facing the Development of Disease Modifying Therapies for Alzheimer’s Disease

09:20—09:40
Coffee Break

11:15—16:30
On Own for Lunch and Recreation

16:00—16:30
Coffee Available

16:30—18:30
LRRK2 Biology and PD Therapeutics
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Marcel P. van der Brug, Genentech, Inc., USA

Mark R. Cookson, NIA, National Institutes of Health, USA
A State-of-the-Protein View of LRKK2

Anthony A. Estrada, Genentech, Inc., USA
Discovery of LRRK2 Small Molecule Inhibitors for the Treatment of PD

Warren D. Hirst, Pfizer Neuroscience Research Unit, USA
Short Talk: Development of Assays to Measure LRRK2 Levels and Activity in Sporadic Parkinson’s Disease Brain

Arjan Kortholt, University of Groningen, Netherlands
Structural Studies on Roco Proteins and Implications for LRRK2

16:30—18:30
AD Prevention versus Intervention Trials
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA
Secondary Prevention Trials in Preclinical Alzheimer’s Disease

Leonard Petrucelli, Mayo Clinic Jacksonville, USA
Short Talk: HDAC6 Inhibition as a Treatment of Tauopathies

Mark S. Forman, Merck, USA
BACE1 Inhibitors for Alzheimer’s Disease

* John Q. Trojanowski, University of Pennsylvania, USA
Concluding Remarks

18:30—19:30
Social Hour w/ Lite Bites

19:30—22:30
Entertainment


FRIDAY, MARCH 7

 
Departure


*Session Chair †Speaker invited, not yet responded.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

Curemark LLC

We gratefully acknowledge additional support for this conference from:

Cellular Dynamics International

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13NS084618-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Bristol-Myers Squibb Company


Genentech, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

EMBO (European Molecular Biology Organization)

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Amanda Deem, Assistant Director of Development, Email: AmandaD@keystonesymposia.org,
Phone:+1 970-262-2668

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676